Clinical Trial: SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer

U.S., July 14 -- ClinicalTrials.gov registry received information related to the study (NCT07697586) titled 'SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer' on July 03.

Brief Summary: This is an open-label, multi-center, Phase II clinical study to evaluate the safety, tolerability, and efficacy of SKB264 in combination with SKB118 in participants with NSCLC. The study includes a dose escalation phase and an expansion phase.

Study Start Date: Aug., 2026

Study Type: INTERVENTIONAL

Condition: NSCLC

Intervention: DRUG: SKB264+SKB118

Administered by intravenous infusion on Day 1 and Day 15 of each 28-day cycle.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Published...